Health: CRISPR Gene Therapy Cleared for Children as Young as Two : A Breakthrough Worth Celebrating

The Report A quiet but monumental shift in medicine arrived this week. The U.S. Food and Drug Administration has expanded approval of Casgevy — the first CRISPR-based gene therapy — to include children as young as two who suffer from sickle cell disease and transfusion-dependent beta-thalassemia.

This is the first time a CRISPR therapy has been approved for such a young age group anywhere in the world. For roughly 5,500 American children who endure recurrent vaso-occlusive crises — episodes of excruciating pain caused by sickle-shaped blood cells blocking vessels — this approval opens the door to a potentially curative treatment where previously there was only management.

Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy uses gene-editing technology to reactivate fetal hemoglobin, effectively correcting the underlying genetic defect. The therapy was originally approved for patients 12 and older in late 2023. Now, families can begin conversations with pediatric hematologists years earlier.

Centered on the Cross Every time science takes a step toward healing, it echoes the heart of a Creator who "heals all your diseases" (Psalm 103:3). Not every disease is cured in this life — we know that. But when a child who once lived in recurring pain might now live free, that is a foretaste of the restoration Jesus promised. It is not an accident that the human mind can unlock the language of DNA. That capacity itself is a gift. And when it is used to relieve suffering, it becomes worship.

Let us thank God for the researchers, the families who never gave up hope, and the children who may now run without fear.

Your Next Step Consider supporting a sickle cell advocacy organization this week. And tonight, if you have healthy children — or a healthy body — take a moment to thank God for that gift.